Richard Drake to Pancreatic Neoplasms
This is a "connection" page, showing publications Richard Drake has written about Pancreatic Neoplasms.
Connection Strength
1.464
-
Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues. Mol Cell Proteomics. 2021; 20:100012.
Score: 0.557
-
MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One. 2014; 9(9):e106255.
Score: 0.361
-
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clin Cancer Res. 2021 01 01; 27(1):226-236.
Score: 0.138
-
The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Clin Cancer Res. 2019 05 01; 25(9):2745-2754.
Score: 0.122
-
The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep. 2017 06 22; 7(1):4020.
Score: 0.110
-
Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
Score: 0.098
-
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78.
Score: 0.079